Ensysce Biosciences Stock Fundamentals
| ENSCWDelisted Stock | USD 0.01 0.0008 8.16% |
Ensysce Biosciences fundamentals help investors to digest information that contributes to Ensysce Biosciences' financial success or failures. It also enables traders to predict the movement of Ensysce Pink Sheet. The fundamental analysis module provides a way to measure Ensysce Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ensysce Biosciences pink sheet.
Ensysce |
Ensysce Biosciences Company Cash Flow From Operations Analysis
Ensysce Biosciences' Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current Ensysce Biosciences Cash Flow From Operations | (8.24 M) |
Most of Ensysce Biosciences' fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ensysce Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
CompetitionIn accordance with the recently published financial statements, Ensysce Biosciences has (8.24 Million) in Cash Flow From Operations. This is 101.56% lower than that of the Healthcare sector and 113.18% lower than that of the Biotechnology industry. The cash flow from operations for all United States stocks is 100.85% higher than that of the company.
Ensysce Biosciences Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Ensysce Biosciences's current stock value. Our valuation model uses many indicators to compare Ensysce Biosciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Ensysce Biosciences competition to find correlations between indicators driving Ensysce Biosciences's intrinsic value. More Info.Ensysce Biosciences is one of the top stocks in ebitda category among its peers. It also is one of the top stocks in net income category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Ensysce Biosciences' earnings, one of the primary drivers of an investment's value.Ensysce Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ensysce Biosciences' direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Ensysce Biosciences could also be used in its relative valuation, which is a method of valuing Ensysce Biosciences by comparing valuation metrics of similar companies.Ensysce Biosciences is currently under evaluation in cash flow from operations category among its peers.
Ensysce Fundamentals
| EBITDA | (27.79 M) | ||||
| Net Income | (29.15 M) | ||||
| Total Debt | 4.44 M | ||||
| Cash Flow From Operations | (8.24 M) | ||||
| Total Asset | 16.42 M | ||||
| Z Score | -3.3 | ||||
| Net Asset | 16.42 M |
About Ensysce Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ensysce Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ensysce Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ensysce Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Ensysce Biosciences, Inc., a clinical-stage biotech company, engages in developing various prescription drugs. Its products treat severe pain and assist in preventing deaths caused by opioid abuse. Ensysce Biosciences operates under Biotechnology classification in the United States and is traded on OTC Exchange.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Other Consideration for investing in Ensysce Pink Sheet
If you are still planning to invest in Ensysce Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Ensysce Biosciences' history and understand the potential risks before investing.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |